Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.
暂无分享,去创建一个
R. Storb | B. Sandmaier | D. Maloney | B. Storer | M. Mielcarek | Paul J. Martin | P. Becker | M. Fang | G. Georges | L. Holmberg | D. Green | M. Bouvier | P. Martin | D. Green | D. Green
[1] N. Kröger,et al. In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review , 2017, Bone Marrow Transplantation.
[2] W. Bensinger,et al. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? , 2017, Current Hematologic Malignancy Reports.
[3] S. Giralt,et al. Recommend upfront consolidation with high-dose melphalan and autologous stem cell support. , 2016, Seminars in oncology.
[4] H. Einsele,et al. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] H. Goldschmidt,et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[6] A. Palumbo,et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[7] H. Goldschmidt,et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.
[8] Raghupathy,et al. Proteasome Inhibitors in the Treatment of Multiple Myeloma , 2016 .
[9] S. Lonial,et al. How I treat high-risk myeloma. , 2015, Blood.
[10] H. Goldschmidt,et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Parmar,et al. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. , 2015, Clinical lymphoma, myeloma & leukemia.
[12] M. Beksac,et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. , 2013, Blood.
[13] M. Kersten,et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Ballestrero,et al. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. , 2012, Seminars in hematology.
[15] P. Moreau. Death of frontline allo-SCT in myeloma. , 2012, Blood.
[16] M. Kersten,et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. , 2012, Blood.
[17] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[18] R. Storb,et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center , 2012, Bone Marrow Transplantation.
[19] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[20] N. Geller,et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. , 2011, The Lancet. Oncology.
[21] M. Kersten,et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. , 2011, Blood.
[22] H. Goldschmidt,et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Meroni,et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies , 2011, Nature Reviews Rheumatology.
[24] K. Anderson. Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment , 2011, Clinical Cancer Research.
[25] M. Khamashta,et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies , 2011, Lupus.
[26] R. Levy,et al. Antiphospholipid Syndrome Clinical Research Task Force Report , 2011, Lupus.
[27] R. Fanin,et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. , 2010, Blood.
[28] D. Hose,et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation , 2010, Haematologica.
[29] P. Richardson,et al. How I treat multiple myeloma in younger patients. , 2009, Blood.
[30] S. Takagi,et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome , 2009, International journal of medical sciences.
[31] W. Murphy,et al. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[32] R. Orlowski,et al. Proteasome inhibitors in the treatment of multiple myeloma , 2009, Leukemia.
[33] A. Stewart,et al. Reduced-intensity allogeneic transplantation for myeloma: reality bites. , 2009, Blood.
[34] P. Moreau,et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma , 2008, Haematologica.
[35] I. Yakoub-Agha,et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. , 2008, Blood.
[36] J. S. San Miguel,et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. , 2008, Blood.
[37] D. Blaise,et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma , 2008, Haematologica.
[38] J. Fareed,et al. Controversies and unresolved issues in antiphospholipid syndrome pathogenesis and management. , 2008, Hematology/oncology clinics of North America.
[39] M. Khamashta,et al. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. , 2007, Arthritis and rheumatism.
[40] P. Sonneveld,et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[42] R. Fanin,et al. A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.
[43] N. Kröger,et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. , 2006, Experimental hematology.
[44] J. Bourhis,et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. , 2006, Blood.
[45] J. Eikelboom,et al. Management of antiphospholipid antibody syndrome: a systematic review. , 2006, JAMA.
[46] Jason McCoy,et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Y. Shoenfeld,et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.
[48] T. Sayers,et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. , 2005, Blood.
[49] M. V. van Oers,et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. , 2004, Blood.
[50] J. Serody,et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[51] R. Sacco,et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. , 2004, JAMA.
[52] R. Storb,et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.
[53] J. Douketis,et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. , 2003, The New England journal of medicine.
[54] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[55] N. Kröger,et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.
[56] K. Furie,et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. , 2001, The New England journal of medicine.
[57] M. V. van Oers,et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] R. Collins,et al. Donor leukocyte infusions for multiple myeloma , 2000, Bone Marrow Transplantation.
[59] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[60] R. Marcus,et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. , 1996, Blood.
[61] G. Gahrton,et al. Graft-versus-myeloma effect , 1996, The Lancet.
[62] B. Barlogie,et al. Graft-versus-myeloma effect: proof of principle. , 1996, Blood.
[63] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[64] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.